By restoring brain perfusion, mTOR attenuation would have the potential to delay disease onset or decrease severity of disease in AD, or mitigate age-related cognitive and cerebrovascular dysfunction in individuals that do not convert to AD. This evidence concerns the gene MTOR and Alzheimer disease.